Nigel Trim is a graduate pharmacologist, with 35 years’ experience in the clinical development and commercialisation of Pharmaceutical, Biotechnology and Medical Device products. As director, founder and investor he has grown a number of companies through to their successful sale, managing businesses of up to 200 employees. Mr Trim has direct experience running pharma and med-tech development programmes throughout Europe, Central and Eastern Europe, North America, North Africa and Asia Pacific.
John Callan is the Norbrook chair in pharmaceutical science at Ulster University. A co-inventor of the SonoTarg IP and a chemist by training with interests in medicinal chemistry and drug delivery, he has 20+ years’ experience (both academic and industrial) in the discovery, development and formulation of new drug candidates.
Tony McHale is professor of medical biotechnology at Ulster University. A co-inventor of the SonoTarg IP and a biochemist by training, with significant expertise in bioengineering and a long-standing interest in stimulus-responsive drug/gene delivery, he has previous experience in the creation, pre-clinical development and early stage clinical testing of an ultrasound-based therapy (CEFUS) for cancer.
Eleanor Stride, FREng, OBE is a statutory Professor in Biomedical Engineering at the University of Oxford. A co-inventor of the SonoTarg IP, she specialises in ultrasound and cavitation physics and their application in stimuli responsive drug delivery.
Mark Love is consultant radiologist at the Royal Victoria hospital in Belfast. Dr Love has 25 years’ experience in cancer diagnosis and staging using a variety of techniques including CT, MRI and endoscopic ultrasound.
Mark Taylor is the lead Hepato Pancreato Biliary (HPB) surgeon in Northern Ireland, President Elect of Great Britain and Ireland Hepato Pancreato Biliary Association (GBIHPBA) and Director of Education, Research and Training for the Association of Upper G.I. Surgeons of Great Britain and Ireland (AUGIS). Prof Taylor has also advised the National Institute for Health and Care Excellence (NICE) on the use of the CyberKnife System (Accuray Inc.) in the treatment of pancreatic cancer.